a P < .001 for trend for all comparisons using the Cuzick test.
Bariatric surgery is the most effective therapy available for significant and sustainable weight loss in patients with morbid obesity.
1,2 As a result of the increasing prevalence of obesity, improvements in perioperative safety, and expanded insurance coverage, bariatric surgery use has increased during the last decade. 3, 4 Changes in procedure use over time reflect emerging evidence regarding the comparative safety and effectiveness of available procedures.
1,2,5 An understanding of current trends in bariatric procedure use can inform primary care physicians counseling patients with morbid obesity who are considering surgical intervention. Although recent reports have documented an increased use of sleeve gastrectomy (SG) In brief, trained data abstractors review the medical record and collect information on patient demographics, comorbidities, intraoperative and perioperative processes, and 30-day outcomes of all patients undergoing bariatric surgery in participating hospitals. The hospitals are audited annually to ensure data accuracy. There are no missing data. This study was considered exempt by the institutional review board at the University of Michigan.
We calculated relative use stratified by procedure type and year of procedure, and we examined procedure rates within clinically important subgroups. The Cuzick test for trend was used to assess differences in procedure use across years, and the χ 2 test was used to evaluate differences in procedure use between subgroups. All P values are 2-tailed with α set at .05. Statistical analyses were performed using Stata version 12.1 (StataCorp).
Results | The final cohort included 43 732 patients undergoing bariatric surgery. As shown in the Figure, relative use of SG increased from 6.0% (95% CI, 5.4%-6.6%) of all procedures in 2008 to 67.3% (95% CI, 66.0%-68.6%) of all procedures in 2013, which is an increase of 61%. During the same period, use of RYGB decreased from 58.0% (95% CI, 56.8%-59.1%) to 27.4% (95% CI, 26.2%-28.6%), and use of LAGB decreased from 34.5% (95% CI, 33.3%-35.6%) to 4.6% (95% CI, 4.1%-5.2%). Changes in surgery use over time within clinically important subgroups (Table) were similar to the overall trend. Use of SG increased, whereas rates of RYGB and LAGB decreased. Even though SG was the most common procedure across all subgroups in 2012 and 2013, SG rates were relatively lower in patients aged 65 years or older ( Discussion | Analysis of recent practice in Michigan revealed SG to be the most common procedure performed for patients pursuing bariatric surgery, surpassing RYGB in 2012. Moreover, despite controversy regarding the optimal procedure for patients with gastroesophageal reflux disease and type 2 diabetes, 1 SG has become the predominant procedure in both groups. This analysis is limited to procedures performed in a single state. Although use of this detailed bariatric-specific registry in Michigan allows for a more accurate assessment of trends in procedure use than administrative data, it may limit the generalizability of our results. Although unmeasured confounders may influence procedure use, this bias is unlikely to alter these findings given the large magnitude of the differences observed. Although long-term outcomes of SG are still unclear, these changes may reflect the favorable perioperative safety profile and emerging evidence of successful weight loss at 2 to 3 years after SG.
5 These findings are important to inform primary care physicians of the predominant bariatric procedure currently used, regardless of preexisting comorbidity, and may assist in the preoperative counseling of patients considering surgical therapy for morbid obesity. In Reply As Drs Kwak and Kim note, the Prehospital Acute Neurological Treatment and Optimization of Medical Care in Stroke Study (PHANTOM-S) used randomization by weeks instead of at the patient level, and this was an acknowledged limitation of our study. However, independent of STEMO or control week and independent of actual STEMO availability during STEMO weeks, dispatchers at the dispatch center activated a stroke alarm if stroke was suspected during an emergency call. All patients for whom a stroke alarm was activated were eligible for the study. Apart from the 1 additional ambulance (ie, STEMO) that was available in addition to the approximately 30 ambulances in the catchment area during STEMO weeks, there were no other additional resources available during STEMO weeks compared with control weeks and no specific additional treatment was given to patients for whom a regular ambulance was deployed during STEMO weeks.
Slightly more patients who received conventional treatment during STEMO weeks received tPA (24.1% vs 21.1%, P = .20) or were transported to a stroke unit during STEMO weeks compared with control weeks (90.9% vs 87.3%, P = .02) (Table) . For both parameters, the differences between patients with and without STEMO deployment were more substantial.
Comparing patients with conventional care during STEMO weeks with patients in control weeks with regard to the suggested parameters (Table) , no other significant differences could be detected.
We are not able to completely rule out selective deployment during the dispatch process. However, with similar num-
